Summary of SGLT2i-associated erythrocytosis retrospective cohort studies
| Study . | N . | Population . | Male, n (%) . | Age∗, y . | Baseline Hb∗, g/L . | Peak Hb∗, g/L . | Hb change†, g/L . | Thrombotic events, n (%) . |
|---|---|---|---|---|---|---|---|---|
| Liu et al2 | 75 | Hematology | 56 (68.3) | 63 (30-85) | 161 (114-190) | 185 (162-216) | +24 | 5 (6.7) |
| Gangat et al3 | 30 | Diabetes | 20 (67) | 64 (29-81) | 158 (134-169) | 179 (153-198) | +21 | 2 (7) |
| Gangat et al4 | 100‡ | Diabetes | 78 (78) | 62 (29-87) | 155 (120-179) | 180 (151-210) | +25 | 10 (10) |
| Gill et al5 | 42 | Renal transplant | 32 (76) | 59 ± 12.3 | NA | NA | NA | 1 (2.4) |
| Lassen et al6 | 7926 | Nationwide | 3028 (38) | 60.7 ± 11.7 | 142 ± 15 | NA | +4.3 | NA |
| Study . | N . | Population . | Male, n (%) . | Age∗, y . | Baseline Hb∗, g/L . | Peak Hb∗, g/L . | Hb change†, g/L . | Thrombotic events, n (%) . |
|---|---|---|---|---|---|---|---|---|
| Liu et al2 | 75 | Hematology | 56 (68.3) | 63 (30-85) | 161 (114-190) | 185 (162-216) | +24 | 5 (6.7) |
| Gangat et al3 | 30 | Diabetes | 20 (67) | 64 (29-81) | 158 (134-169) | 179 (153-198) | +21 | 2 (7) |
| Gangat et al4 | 100‡ | Diabetes | 78 (78) | 62 (29-87) | 155 (120-179) | 180 (151-210) | +25 | 10 (10) |
| Gill et al5 | 42 | Renal transplant | 32 (76) | 59 ± 12.3 | NA | NA | NA | 1 (2.4) |
| Lassen et al6 | 7926 | Nationwide | 3028 (38) | 60.7 ± 11.7 | 142 ± 15 | NA | +4.3 | NA |
Hematology population included all undifferentiated patients presenting to a hematology clinic with erythrocytosis; diabetes population included consecutive patients with diabetes mellitus with erythrocytosis; renal transplant population included patients with erythrocytosis after kidney transplant; nationwide population included patients from the Danish national registry.
Hb, hemoglobin; NA, not available.
Median (range) or mean ± standard deviation.
Median or mean change.
Included the 30 patients from Gangat et al3 with additional follow-up.